Jason B. Daly - 02 Mar 2026 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role
EVP, Chief Legal Officer
Signature
/s/ Denis Butkovic, Attorney-in-Fact
Issuer symbol
AMRX
Transactions as of
02 Mar 2026
Net transactions value
$0
Form type
4
Filing time
03 Mar 2026, 16:27:20 UTC
Previous filing
13 Aug 2025
Next filing
05 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Daly Jason B. EVP, Chief Legal Officer C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER /s/ Denis Butkovic, Attorney-in-Fact 03 Mar 2026 0001906486

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMRX Restricted Stock Units Award $0 +65,359 $0.000000 65,359 02 Mar 2026 Class A Common Stock 65,359 Direct F1, F2
transaction AMRX Performance-Based Restricted Stock Units Award $0 +65,359 $0.000000 65,359 02 Mar 2026 Class A Common Stock 65,359 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2 The restricted stock units vest in four equal annual installments beginning on March 2, 2027.
F3 Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F4 Represents a performance-based restricted stock unit grant of 65,359 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.